ERBB2 and breast cancer: As a potential therapeutic target, HER2 has been assessed in clinical trials using anti-HER2 monoclonal antibodies and tyrosine-kinase inhibitors, either in monotherapy or combined with conventional chemotherapy, as second-line treatments in patients with advanced or metastatic BC; however, such phase II trials did not yield acceptable results, with low overall response rates [16].